<DOC>
	<DOCNO>NCT00003028</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness MEN-10755 treating adult recurrent refractory solid tumor .</brief_summary>
	<brief_title>MEN-10755 Treating Adults With Recurrent Refractory Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) MEN-10755 patient recurrent refractory adult solid tumor . II . Determine qualitative quantitative toxic effect MEN-10755 study predictability , duration , intensity , onset , reversibility , dose relationship toxic effect patient . III . Propose safe dose phase II study . IV . Assess pharmacokinetics MEN-10755 different dose level patient . V. Document possible antitumor activity MEN-10755 . OUTLINE : This open label , nonrandomized study . Patients receive MEN-10755 single 15 minute intravenous infusion every 3 week , upon recovery toxicity . Doses escalate decrease rate depend clinical judgement investigator . The MTD dose dose limit toxicity observe least 2 6 patient give dose level . Patients remove study cardiac toxicity , disease progression , renal , cardiac pulmonary decline present . PROJECTED ACCRUAL : At least 5 evaluable patient enrol .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : See General Eligibility Criteria PATIENT CHARACTERISTICS : Age : 18 Performance Status : WHO 02 Life Expectancy : At least 3 month Hematopoietic : ANC least 2,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Liver function test great 2 time upper limit normal ( ULN ) ( unless relate liver metastasis , great 5 time ULN ) Renal : Creatinine great 1.4 mg/dL Creatinine clearance least 60 mL/min Cardiovascular : LVEF great 50 % ( measure MUGA scan ) Other : Not pregnant nursing Effective contraceptive method must use study No active bacterial infection No nonmaliganant diseases No history alcoholism drug abuse No psychosis PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy within 4 week study Concurrent use growth factor allow case febrile neutropenia ( prophylactic use allow ) Chemotherapy : No prior chemotherapy within 4 week study No prior nitrosoureas , mitomycin , high dose carboplatin within 6 week study Endocrine therapy : No concurrent corticosteroid ( unless approve clinical investigator ) Radiotherapy : No prior radiotherapy within 4 week study No prior extensive radiotherapy within 6 week study Surgery : Not specify Other : No prior experimental therapy No prior anthracyclines anthracenediones</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>